NASDAQ:BPTH

Bio-Path - BPTH Stock Forecast, Price & News

$3.94

-0.16 (-3.90%)

(As of 08/17/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.91
▼
$4.09
50-Day Range: $3.43
▼
$4.43
52-Week Range: $2.68
▼
$8.62

Volume: 18,313 shs
Average Volume: 49,297 shs
Market Capitalization: $28.21 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Bio-Path MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 128.4% Upside
$9.00 Price Target
Short Interest: Healthy
3.02% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.18
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.89) to ($1.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

707th out of 1,122 stocks

Pharmaceutical Preparations Industry

355th out of 551 stocks

3.5

Analyst's Opinion

Consensus Rating
Bio-Path has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.00, Bio-Path has a forecasted upside of 128.4% from its current price of $3.94.
Amount of Analyst Coverage
Bio-Path has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.02% of the float of Bio-Path has been sold short.
Short Interest Ratio / Days to Cover
Bio-Path has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Bio-Path has recently decreased by 2.07%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Bio-Path does not currently pay a dividend.
Dividend Growth
Bio-Path does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BPTH.

2.9

News and Social Media Coverage

News Sentiment
Bio-Path has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Bio-Path this week, compared to 4 articles on an average week.
Search Interest
2 people have searched for BPTH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
1 people have added Bio-Path to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bio-Path insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.28% of the stock of Bio-Path is held by insiders.
Percentage Held by Institutions
Only 6.29% of the stock of Bio-Path is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Bio-Path are expected to grow in the coming year, from ($1.89) to ($1.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bio-Path is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bio-Path is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bio-Path has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bio-Path (NASDAQ:BPTH) Stock

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. StockNews.com assumed coverage on Bio-Path in a research report on Wednesday. They set a "sell" rating on the stock. HC Wainwright lowered their price target on Bio-Path from $12.00 to $9.00 and set a "buy" rating on the stock in a report on Wednesday, May 18th.

Bio-Path Stock Performance

Shares of BPTH Stock traded down $0.03 on Wednesday, reaching $4.10. 23,423 shares of the company's stock traded hands, compared to its average volume of 30,145. Bio-Path has a 12-month low of $2.68 and a 12-month high of $8.62. The company has a market capitalization of $29.36 million, a P/E ratio of -2.55 and a beta of 1.48. The business's 50 day moving average price is $3.88 and its two-hundred day moving average price is $3.58.

Bio-Path (NASDAQ:BPTH - Get Rating) last issued its quarterly earnings results on Tuesday, August 16th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.08. During the same period in the previous year, the company posted ($0.26) EPS. Research analysts predict that Bio-Path will post -1.89 earnings per share for the current year.

Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

BPTH Stock News Headlines

August 17, 2022 | bloomberg.com

Bluebird's Game-Changing Therapy for Rare Blood Disorder Cleared by FDA - Bloomberg

August 16, 2022 | investing.com

Bio-Path Holdings Tops Q2 EPS by 8c By Investing.com - Investing.com

August 16, 2022 | finance.yahoo.com

Bio-Path Holdings Reports Second Quarter 2022 Financial Results

August 15, 2022 | finance.yahoo.com

Tarsier Pharma announces development of TRS02, a potential immunomodulator, for the treatment of retinal diseases with sustained-release intravitreal formulation - Yahoo Finance

August 12, 2022 | bloomberg.com

Inotiv, Inc. Announces Third Quarter Fiscal 2022 Financial Results - Bloomberg

August 10, 2022 | benzinga.com

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans - Benzinga

August 10, 2022 | globenewswire.com

Inotiv, Inc. Announces Third Quarter Fiscal 2022 Financial Results - GlobeNewswire

August 9, 2022 | finance.yahoo.com

Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022 - Yahoo Finance

August 9, 2022 | finance.yahoo.com

Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022

August 7, 2022 | seekingalpha.com

Chembio Diagnostics, Inc.'s (CEMI) CEO Rick Eberly on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

August 4, 2022 | cnbc.com

How to become an influencer on TikTok or Instagram - CNBC

August 4, 2022 | fool.com

INmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript - The Motley Fool

August 3, 2022 | americanbankingnews.com

StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH)

August 2, 2022 | nytimes.com

Is Bio-Designed Collagen the Next Step in Animal Protein Replacement? - The New York Times

July 31, 2022 | nittanylionswire.usatoday.com

Penn State top 25 players in 2022: Landon Tengwall - Nittany Lions Wire

July 27, 2022 | finance.yahoo.com

Portfolio Highlights: Clinical and Financing Updates of AIxplorerBIO, Genhouse, VivaVision, Domain, Amberstone, Anji and QurAlis - Yahoo Finance

July 27, 2022 | businesswire.com

Curi Bio Launches Mantarray™ Platform – 3D Engineered Muscle Tissues for Discovery of New Therapeutics - Business Wire

July 26, 2022 | businesswire.com

Akanda to Contest Unauthorized Liquidation of its Lesotho-Based Subsidiary, Bophelo Bio Science & Wellness (Pty) Ltd. - Business Wire

July 26, 2022 | seekingalpha.com

Zymergen Stock: Upcoming Ginkgo Bioworks Acquisition (NASDAQ:ZY) - Seeking Alpha

July 26, 2022 | fool.com

IVERIC bio, Inc. (ISEE) Q2 2022 Earnings Call Transcript - The Motley Fool

July 25, 2022 | techcrunch.com

Dead spiders: nature’s robot hands - TechCrunch

July 25, 2022 | forbes.com

For Bio Manufacturing To Scale, It Has To Think Outside The Tank - Forbes

July 25, 2022 | americanbankingnews.com

Bio-Path (NASDAQ:BPTH) Receives New Coverage from Analysts at StockNews.com

July 20, 2022 | latimes.com

Tanya Kersey, Hollywood Black Film fest founder, dies at 61 - Los Angeles Times

July 20, 2022 | nasdaq.com

Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy - Nasdaq

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

BPTH Company Calendar

Last Earnings: 8/16/2022
Today: 8/17/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BPTH
CUSIP: N/A
CIK: 1133818
Web: www.biopathholdings.com
Phone: (832) 742-1357
Fax: N/A
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.00
High Stock Price Forecast: $9.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +128.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,440,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -42.49%
Return on Assets: -40.38%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.06
Quick Ratio: 15.06

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.56 per share
Price / Book: 1.11

Miscellaneous

Outstanding Shares: 7,160,000
Free Float: 6,997,000
Market Cap: $28.21 million
Optionable: Not Optionable
Beta: 1.48

Key Executives

Mr. Peter H. Nielsen MBA (Age 73)
Co-Founder, Chairman, CEO, Pres, CFO & Treasurer
Comp: $680.18k
Mr. Douglas P. Morris (Age 66)
Co-Founder, Director of Investor Relations, Sec. & Director
Comp: $68.47k
Mr. Anthony Price
Sr. VP of Fin., Accounting & Admin.
Dr. Ana Tari Ashizawa Ph.D.
MBA, Sr. VP of Research, Devel. & Clinical Design
Dr. Alan MacKenzie Ph.D.
Consultant
Dr. Thomas A. Walker Ph.D.
Consultant
Dr. Jeffery Lancet M.D.
Consultant
Ms. Victoria Lake Rac
Regulatory Consultant

Key Competitors

View All Competitors

Insiders & Institutions

Renaissance Technologies LLC
Bought 18,000 shares on 8/13/2022
Ownership: 0.251%

View All Insider Transactions
View All Institutional Transactions

BPTH Stock - Frequently Asked Questions

Should I buy or sell Bio-Path stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPTH shares.
View BPTH analyst ratings or view top-rated stocks.
What is Bio-Path's stock price forecast for 2022?: 1 equities research analysts have issued 12-month price targets for Bio-Path's shares. Their BPTH share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 128.4% from the stock's current price.
View analysts price targets for BPTH or view top-rated stocks among Wall Street analysts.
How have BPTH shares performed in 2022?: Bio-Path's stock was trading at $3.77 at the beginning of 2022. Since then, BPTH shares have increased by 4.5% and is now trading at $3.94.
View the best growth stocks for 2022 here.
When is Bio-Path's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our BPTH earnings forecast.
How were Bio-Path's earnings last quarter?: Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its quarterly earnings data on Tuesday, August, 16th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.08. During the same period in the previous year, the firm posted ($0.26) EPS.
When did Bio-Path's stock split?: Bio-Path's stock reverse split on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Bio-Path own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).
What is Bio-Path's stock symbol?: Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."
Who are Bio-Path's major shareholders?: Bio-Path's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.25%).
View institutional ownership trends.
How do I buy shares of Bio-Path?: Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Bio-Path's stock price today?: One share of BPTH stock can currently be purchased for approximately $3.94.
How much money does Bio-Path make?: Bio-Path (NASDAQ:BPTH) has a market capitalization of $28.21 million. The company earns $-10,440,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis.
How can I contact Bio-Path?: Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The official website for the company is www.biopathholdings.com. The company can be reached via phone at (832) 742-1357 or via email at will@sternir.com.

This page (NASDAQ:BPTH) was last updated on 8/18/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Bio-Path - BPTH Stock Forecast, Price & News

Bio-Path MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month